Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway

Abstract

Background Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple cancer types. However, the roles and the underlying mechanism of fibronectin on the progression NSCLC need to be further elucidated. Methods Public dataset such as Kaplan-Meier Plotter was used to determine the prognostic significance of genes. The correlation of different protein expression in clinical and xenograft tissues was tested by immunohistochemistry experiment. Both in vitro and in vivo experiments were performed to determine the role of fibronectin on the tumor growth, metastasis, and angiogenesis in NSCLC. The activation of key signaling pathway under fibronectin was examined by WB assay. RNA-seq was applicated to screening the target gene of fibronectin. Rescue experiment was performed to confirm the role of target gene in fibronectin-mediated function in NSCLC. Finally, luciferase and CHIP assays were used to elucidate the mechanism by which fibronectin regulated the target gene. Results Our results revealed that fibronectin was up-regulated in cancer tissues compared with the normal ones in NSCLC patients. Dish- coated fibronectin enhanced the tumor growth, metastasis, and angiogenesis of NSCLC in vitro and in vivo by promoting EMT and maintaining stemness of NSCLC cells. As expected, fibronectin activated FAK and its downstream MAPK/ERK signaling pathway. WISP3 was screened as a potential target gene of fibronectin. Interestingly, WISP3 effectively activated Wnt signaling pathway, and knockdown of WISP3 effectively blocked the influence of fibronectin on the migration, invasion and vascular structure formation potential of NSCLC cells. Our data also manifested that fibronectin elevated the transcription of WISP3 gene by promoting the binding of HIF-1α to the promoter region of WISP3 in NSCLC cells. Conclusions Our findings sketched the outline of the route for fibronectin exert its role in NSCLC, in which fibronectin activated downstream FAK and MAPK/ERK signaling pathways, and mediated the accumulation of HIF-1α. Then, HIF-1α enabled the transcription of WISP3, and subsequently promoted the activation of Wnt signaling pathway, and finally enhanced the tumor growth, metastasis, and angiogenesis in NSCLC.

Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

“…Angiogenesis is one of the hallmarks of cancer and blood vessels are also the important components of the TME [ 11 , 27 ]. Notably, previous evidence showed that FAK pathway was associated with angiogenesis and tumor growth [ 28 – 30 ]. Therefore, we questioned whether the use of FAK inhibitor has an impact on TME via inhibiting tumor angiogenesis in KL tumors.…”

Engineered in vivo and in vitro tumor model recapitulates vasculogenic mimicry signatures in melanoma

“… 40 , 41 In lung cancer, FN expression is abnormal, especially in non‐small cell lung cancer. 42 , 43 Moreover, recent evidence suggests that VM formation is frequently observed in ECM‐rich regions containing large amounts of proteins such as collagen and FN. 44 Consistent with the properties of matrix, alteration in collagen and FN concentration may directly impact cellular behavior.…”

Comprehensive analysis of Linc01436 for neoadjuvant chemotherapy response and its potential enriched pathways in breast cancer

“…Previous studies reported that the activation of MAPK1 was linked to promoting paclitaxel-based chemotherapy resistance in breast cancer [29,30]. It was also reported that MAPK/ERK signaling pathway could stimulate the accumulation of HIF-1α to promote NSCLC progression [31]. Therefore, these previous ndings provide us a consideration that activated MAPK/ERK pathway might enhance HIF-1α expression to drive Linc01436 overexpression which provokes Ras/Raf/ERK signaling pathway leading to poor response of NAC for breast cancer patients.…”